View filters (6 in use)

Updating results

575 results

Sort: Relevance | Date

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

In development [GID-TA10580] Expected publication date: TBC

Technology appraisal guidance In development

Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]

In development [GID-TA10579] Expected publication date: 21 April 0201

Technology appraisal guidance In development

Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]

In development [GID-TA10578] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]

In development [GID-TA10576] Expected publication date: TBC

Technology appraisal guidance In development

Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

In development [GID-TA10575] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab in combination for untreated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID2700]

In development [GID-TA10574] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

In development [GID-TAG363] Expected publication date: TBC

Technology appraisal guidance In development

Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260

In development [GID-TA10309] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib for untreated mantle cell lymphoma (ID1221)

In development [GID-TA10185] Expected publication date: TBC

Technology appraisal guidance In development

Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

In development [GID-TA10248] Expected publication date: TBC

Technology appraisal guidance In development

Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

In development [GID-TA10361] Expected publication date: TBC

Technology appraisal guidance In development

Short bowel syndrome - teduglutide [ID885]

In development [GID-TA10048] Expected publication date: TBC

Technology appraisal guidance In development

Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

In development [GID-TA10448] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Nivolumab in combination for untreated advanced gastric cancer [ID1465]

In development [GID-TA10352] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605

In development [GID-TA10488] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (metastatic) - talimogene laherparepvec [ID508]

In development [GID-TAG509] Expected publication date: 28 September 2016

Technology appraisal guidance In development

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494

In development [GID-TA10424] Expected publication date: TBC

Technology appraisal guidance In development

Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]

In development [GID-TA10168] Expected publication date: TBC

Technology appraisal guidance In development

Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

In development [GID-TAG496] Expected publication date: TBC

Technology appraisal guidance In development

Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

In development [GID-TAG494] Expected publication date: TBC

Technology appraisal guidance In development

Diabetes - buccal insulin [ID311]

In development [GID-TAG244] Expected publication date: TBC

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development

Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

In development [GID-TA10483] Expected publication date: TBC

Technology appraisal guidance In development

Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466

In development [GID-TA10355] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for treating interstitial lung disease caused by systemic sclerosis (ID1420)

In development [GID-TA10427] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, EGFR and T790M positive, metastatic) - osimertinib (CDF Review of TA416) [ID1577]

In development [GID-TA10475] Expected publication date: 22 April 2020

Technology appraisal guidance In development

Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable ID1564

In development [GID-TA10478] Expected publication date: 10 February 2021

Technology appraisal guidance In development

Spasticity (after stroke) - botulinum toxin type A [ID768]

In development [GID-TAG499] Expected publication date: TBC

Technology appraisal guidance In development

Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

In development [GID-TA10105] Expected publication date: TBC

Technology appraisal guidance In development

Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

In development [GID-TA10179] Expected publication date: TBC

Technology appraisal guidance In development

Solriamfetol for treating excessive sleepiness caused by obstructive sleep apnoea [ID1499]

In development [GID-TA10430] Expected publication date: 27 January 2021

Technology appraisal guidance In development

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

In development [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance In development

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 August 2020

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]

In development [GID-TA10433] Expected publication date: TBC

Technology appraisal guidance In development

Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444

In development [GID-TA10477] Expected publication date: TBC

Technology appraisal guidance In development

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Technology appraisal guidance In development

Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

In development [GID-TA10122] Expected publication date: TBC

Technology appraisal guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 05 June 2020

Technology appraisal guidance In development

Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]

In development [GID-TA10119] Expected publication date: 01 July 2020

Technology appraisal guidance In development

Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492

In development [GID-TA10441] Expected publication date: TBC

Technology appraisal guidance In development

Veliparib with carboplatin and paclitaxel for untreated epithelial ovarian, fallopian tube or primary peritoneal cancer ID1561

In development [GID-TA10442] Expected publication date: TBC

Technology appraisal guidance In development

Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

In development [GID-TA10089] Expected publication date: 15 November 2017

Technology appraisal guidance In development

Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

In development [GID-TA10024] Expected publication date: 28 June 2017

Technology appraisal guidance In development

Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

In development [GID-TA10254] Expected publication date: TBC

Technology appraisal guidance In development

Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

In development [GID-TA10046] Expected publication date: 22 November 2017

Technology appraisal guidance In development

Nintedanib for untreated malignant pleural mesothelioma (ID1424)

In development [GID-TA10359] Expected publication date: TBC

Technology appraisal guidance In development